

Medical Research Agency

<https://www.abm.gov.pl/en/news/26,Medical-Research-Agency-has-signed-a-letter-of-intent-with-Wroclaw-Medical-Unive.html>
03.05.2024, 09:24

Medical Research Agency has signed a letter of intent with Wroclaw Medical University

Medical Research Agency has signed a letter of intent with Wroclaw Medical University on cooperation in terms of implementation of the "Medical Research Agency" project (task no. 2) within the PO WER project.

The aim of the partnership includes joint preparation of a unique programme of postgraduate studies in the area of non-commercial clinical research implemented in Wroclaw Medical University. The project is addressed to employees of health care facilities and employees of founding bodies of health care facilities. The planned course of the studies includes two editions addressed to the total of 140 participants that form research teams (doctors, coordinators, support personnel, economists, statisticians, lawyers, etc).

The classes shall be held by lecturers of Wroclaw Medical University and experienced workers of the Medical Research Agency. The studies shall include a broad scope of subjects connected to non-commercial clinical research.

The undertaken actions are supposed to extend knowledge and competencies in the area of planning, conducting and monitoring non-commercial clinical research which will further influence increase in the number of clinical studies in our country. The analysis of the condition of clinical research in Poland carried out lately (PwC 2015 report) has showed that Poland's potential in the area of implementation of non-commercial clinical research is significantly unused.

The knowledge gained during the studies offers the opportunity to increase the number of clinical trials conducted in Poland. Thanks to the possibility to study, the participants of the project will gain knowledge that will allow them to make decision on initiating, conducting and proceeding scientific projects which will translate on searching for new diagnostic and therapeutic solutions and may result in changes in reimbursement of health benefits. The



undertaken educational actions also offer a chance to increase the quality and reliability of the studies and improve the knowledge on new treatment methods among patients.

[Previous Page](#)

[Next Page](#)